Exact Sciences (NASDAQ: EXAS) reported Q1 EPS of ($1.04), $0.03 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $487 million versus the consensus estimate of $461.71 million.

GUIDANCE:

Exact Sciences sees FY2022 revenue of $1.985-2.032 billion, versus the consensus of $2.01 billion.

• Screening revenue of $1,350-$1,372 million, including $40-$42 million from PreventionGenetics,
• Precision Oncology revenue of $595-$610 million, and
• COVID-19 testing revenue of $40-$50 million.
• Revenue guidance has been raised and narrowed toward the high end of the previously expected range of $1,975-$2,027 million, which assumed:
• Screening revenue of $1,340-$1,367 million, including $40-$42 million from PreventionGenetics,
• Precision Oncology revenue of $595-$610 million, and
• COVID-19 testing revenue of $40-$50 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.